ArticleFrontiers in oncology2023

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.

Nicolas S H Xander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.